News

The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new…

The U.S. Food and Drug Administration has approved a new dosing regimen for the multiple myeloma treatment Darzalex (daratumumab), allowing doctors to split the first…

Owing to an anonymous $75 million gift, New York University (NYU) Langone Health and its Laura and Isaac Perlmutter Cancer Center will establish…

Real world data from multiple myeloma patients in Hungary supports the use of a triple combination regimen — Ninlaro (ixazomib), Revlimid (lenalidomide), and…

Adding isatuximab to a standard of care treatment of Pomalyst (pomalidomide) and low-dose dexamethasone prolonged the time without cancer progression in adults with relapsed…

A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than three years in multiple myeloma…

Thanks to a £10 million donation (about $13,000,000), Imperial College London will establish a center for multiple myeloma research at the institution’s Hammersmith…

A panel of blood markers that identifies tumors with more active blood vessels may help stratify multiple myeloma patients according to their risk, a study found.

Analysis of thousands of individual cells in multiple myeloma patients allows for a much more precise diagnosis — distinguishing asymptomatic, early-stage patients from those…

The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow — will now be covered…